SALT LAKE CITY, July 28, 2023 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Twistle® by Health Catalyst (Twistle), a leading clinical workflow and patient engagement platform, has met certain key regulatory, security and privacy requirements necessary for earning HITRUST certification.
HITRUST leverages nationally and internationally accepted standards including ISO, NIST, PCI, HIPAA, and others to ensure a comprehensive set of baseline security controls. HITRUST CSF Certified status demonstrates that Twistle by Health Catalyst has met HITRUST's framework that assessed compliance with certain key regulations and industry-defined requirements that collectively aim to appropriately manage security and privacy risk.
"Health Catalyst is pleased to have achieved HITRUST's CSF Certification for Twistle," said Kevin Scharnhorst, CISSP, CISM, CPHIMS, Chief Information Security Officer at Health Catalyst. "We are committed to maintaining industry best practices for information security and data privacy, critical for protecting our clients and our mission."
Health Catalyst's HITRUST CSF-Certified and applicable platforms are:
About Health Catalyst
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its customers leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.
Media Contact:
Amanda Hundt
This email address is being protected from spambots. You need JavaScript enabled to view it.
575-491-0974
Last Trade: | US$7.36 |
Daily Change: | -0.18 -2.39 |
Daily Volume: | 457,587 |
Market Cap: | US$445.060M |
November 06, 2024 November 06, 2024 November 06, 2024 August 27, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB